Oncternal Therapeutics, Inc.: pre-tax income or loss from continuing operations
Pre-tax income or loss from continuing operations for Oncternal Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Oncternal Therapeutics, Inc. financial histories
What this measure means
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
Exact concept: us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2009-01-01 to 2014-12-31. The SEC response was captured on 2026-09-21.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2014-01-01 | 2014-12-31 | -39,411,000 | USD | 2015-03-16 | 10-K · 0001047469-15-002283 |
| 2013-01-01 | 2013-12-31 | -42,111,000 | USD | 2015-03-16 | 10-K · 0001047469-15-002283 |
| 2012-01-01 | 2012-12-31 | -49,751,000 | USD | 2015-03-16 | 10-K · 0001047469-15-002283 |
| 2011-01-01 | 2011-12-31 | -35,501,000 | USD | 2014-03-12 | 10-K · 0001104659-14-018791 |
| 2010-01-01 | 2010-12-31 | 16,460,000 | USD | 2013-03-05 | 10-K · 0001047469-13-002200 |
| 2009-01-01 | 2009-12-31 | -46,494,000 | USD | 2012-03-02 | 10-K · 0001193125-12-093770 |
Related financial histories
- Oncternal Therapeutics, Inc.: total assets
- Oncternal Therapeutics, Inc.: stockholders equity
- Oncternal Therapeutics, Inc.: cash and cash equivalents
- Oncternal Therapeutics, Inc.: net income or loss
- Oncternal Therapeutics, Inc.: operating cash flow
- Oncternal Therapeutics, Inc.: capital expenditure payments
- Oncternal Therapeutics, Inc.: revenue
- Oncternal Therapeutics, Inc.: financing cash flow
- Oncternal Therapeutics, Inc.: investing cash flow
- Oncternal Therapeutics, Inc.: retained earnings or deficit
- Oncternal Therapeutics, Inc.: basic weighted-average shares
- Oncternal Therapeutics, Inc.: diluted weighted-average shares
- Oncternal Therapeutics, Inc.: basic earnings per share
- Oncternal Therapeutics, Inc.: diluted earnings per share
- Oncternal Therapeutics, Inc.: income tax expense or benefit
- Oncternal Therapeutics, Inc.: net property, plant and equipment
- Oncternal Therapeutics, Inc.: share-based compensation expense
- Oncternal Therapeutics, Inc.: operating income or loss
- Oncternal Therapeutics, Inc.: current assets
- Oncternal Therapeutics, Inc.: current liabilities
- Oncternal Therapeutics, Inc.: current accounts payable
- Oncternal Therapeutics, Inc.: net finite-lived intangible assets
- Oncternal Therapeutics, Inc.: net current accounts receivable
- Oncternal Therapeutics, Inc.: operating expenses
- Oncternal Therapeutics, Inc.: selling, general and administrative expense
- Oncternal Therapeutics, Inc.: common shares outstanding
- Oncternal Therapeutics, Inc.: cash including restricted cash
- Oncternal Therapeutics, Inc.: additional paid-in capital
- Oncternal Therapeutics, Inc.: accumulated other comprehensive income or loss
- Oncternal Therapeutics, Inc.: operating lease right-of-use asset
- Oncternal Therapeutics, Inc.: gross property, plant and equipment
- Oncternal Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
- Oncternal Therapeutics, Inc.: other noncurrent assets
- Oncternal Therapeutics, Inc.: other noncurrent liabilities
- Oncternal Therapeutics, Inc.: accrued current liabilities
- Oncternal Therapeutics, Inc.: prepaid expenses and other current assets
- Oncternal Therapeutics, Inc.: net deferred tax assets
- Oncternal Therapeutics, Inc.: profit or loss including noncontrolling interests
- Oncternal Therapeutics, Inc.: comprehensive income or loss
- Oncternal Therapeutics, Inc.: general and administrative expense
- Oncternal Therapeutics, Inc.: depreciation expense
- Oncternal Therapeutics, Inc.: depreciation, depletion and amortization
- Oncternal Therapeutics, Inc.: other nonoperating income or expense
- Oncternal Therapeutics, Inc.: proceeds from issuing common stock
- Oncternal Therapeutics, Inc.: change in accounts receivable
- Oncternal Therapeutics, Inc.: change in inventories
- Oncternal Therapeutics, Inc.: change in accounts payable
Inspect the source
- Entity
- Oncternal Therapeutics, Inc. / CIK 0001260990
- Captured
- 2026-09-21T17:18:09.927Z
- SEC response SHA-256
dcefea30a8ce148cff96c2a2fa09a3b61a34c7954f6f1a0e51956fda420a1d49
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001260990.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))